Portola Pharmaceuticals Announces Phase 2a Safety and Efficacy Cerdulatinib Data to be Presented at the European Hematology A...
May 18 2017 - 8:00AM
Portola Pharmaceuticals Inc.® (Nasdaq:PTLA) today announced
that preclinical and clinical data on cerdulatinib in
relapsed/refractory b-cell malignancies will be presented at the
European Hematology Association (EHA), which is taking place from
June 22-25 in Madrid, Spain.
Cerdulatinib is an investigational oral, dual SYK/JAK kinase
inhibitor in development to treat patients with resistant or
relapsed hematologic cancers. Cerdulatinib inhibits two key
signaling pathways that promote cancer cell growth in certain
hematologic malignancies.
Details regarding the presentations follow.
Oral Presentation Details:
- Presentation Title: The Dual SYK/JAK Inhibitor
Cerdulatinib Demonstrates Complete Inhibition of SYK and JAK and
Rapid Tumor Responses in a Phase 2 Study in Patients with
Relapsed/Refractory B Cell Malignancies
- Presenter: Paul Hamlin, M.D., Memorial
Sloan-Kettering Cancer Center
- Abstract Number: EHA22
- Presentation Date and Time: June 25, 2017 from
9:00-9:15 a.m. UTC
- Location: Hall A
Poster Presentation Details:
- Presentation Title: IL-4 Increases Expression
of Positive Regulators of BCR Signaling in CLL Which Can Be
Overcome by Cerdulatinib
- Presenter: Andrew Steele, Ph.D., Associate
Professor, Medicine, University of Southampton
- Abstract Number: P587
- Presentation Date and Time: June 24, 2017 from
5:30 – 6:00 p.m. UTC
- Location: Poster Hall (Hall 7)
About Portola Pharmaceuticals, Inc.
Portola Pharmaceuticals is a biopharmaceutical company
developing product candidates that could significantly advance the
fields of thrombosis and other hematologic diseases. The Company is
advancing three programs, including betrixaban, an oral, once-daily
Factor Xa inhibitor; AndexXa™ (andexanet alfa), a recombinant
protein designed to reverse the anticoagulant effect in patients
treated with an oral or injectable Factor Xa inhibitor; and
cerdulatinib, a SYK/JAK inhibitor in development to treat
hematologic cancers. Portola's partnered program is focused on
developing selective SYK inhibitors for inflammatory conditions.
For more information, visit http://www.portola.com and follow
the Company on Twitter @Portola_Pharma.
Investors:
Ana Kapor
Portola Pharmaceuticals
ir@portola.com
Media:
Julie Normart
Pure Communications
jnormart@purecommunications.com
415.946.1087
Portola Pharmaceuticals (NASDAQ:PTLA)
Historical Stock Chart
From Mar 2024 to Apr 2024
Portola Pharmaceuticals (NASDAQ:PTLA)
Historical Stock Chart
From Apr 2023 to Apr 2024